Roche Holding Ltd

Investment decisions are made by the board of Roche Holding Ltd, which comprises representatives of the Hoffmann-La Roche family and trusted advisors. The exact composition is not publicly disclosed, but the family retains majority voting control through the holding entity's dual-class share structure. Fiduciary oversight is provided by the board of F. Hoffmann-La Roche AG.

The office leverages its deep network in healthcare and life sciences, built over a century of pharmaceutical operations. Deal flow comes from co-investment relationships with large private equity firms, direct introductions from scientific and medical advisory boards, and proprietary real estate opportunities through its in-house asset management team (per public record).

Roche Holding Ltd functions primarily as a single family office, but its structure is atypical due to its controlling stake in a publicly traded pharmaceutical giant. It operates more like a holding company with a dedicated investment arm, maintaining separate governance from the operating company. The entity does not manage third-party capital.

The family office allocates capital primarily through direct investments and co-investments, though it also commits to select private equity and private credit funds focused on healthcare and infrastructure. Direct deals are preferred to maintain strategic alignment with the family's long-term interests.

The office focuses on later-stage growth equity, established infrastructure assets, and private credit opportunities with stabilized cash flows. It does not engage in early-stage venture capital or speculative technology bets outside of healthcare. Real estate investments typically target core-plus and value-add commercial properties.

The family office avoids direct exposure to fossil fuel extraction, tobacco, and gambling, consistent with Hoffmann-La Roche's ethical framework. It also avoids direct competition with F. Hoffmann-La Roche AG's pharmaceutical pipeline unless the investment is additive to the operating company's strategy.

The wealth originates from the Hoffmann-La Roche family's founding of F. Hoffmann-La Roche AG in 1896, which grew into one of the world's largest pharmaceutical companies. The holding entity consolidates dividends from the operating company and the proceeds of asset sales, reinvesting across a diversified portfolio (per public record).